Leerink Partnrs Forecasts Beigene’s Q1 Earnings (NASDAQ:ONC)

Beigene, Ltd. (NASDAQ:ONC) – Stock analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of Beigene in a research report issued to clients and investors on Monday, April 28th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings of ($0.61) per share for the quarter, down from their prior estimate of ($0.51). The consensus estimate for Beigene’s current full-year earnings is ($5.82) per share. Leerink Partnrs also issued estimates for Beigene’s Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.49 EPS, FY2025 earnings at ($0.23) EPS and FY2027 earnings at $14.00 EPS.

Several other research analysts also recently commented on ONC. Sanford C. Bernstein set a $259.00 price objective on Beigene in a research note on Thursday, March 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $312.00 price objective on shares of Beigene in a research report on Monday. Macquarie lifted their price objective on Beigene from $259.00 to $313.00 and gave the company an “outperform” rating in a research report on Friday, February 28th. JMP Securities set a $348.00 price objective on Beigene in a research report on Friday, February 28th. Finally, JPMorgan Chase & Co. lifted their price objective on Beigene from $311.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, April 21st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Beigene presently has a consensus rating of “Buy” and a consensus price target of $318.88.

Beigene Stock Performance

Shares of Beigene stock opened at $255.64 on Thursday. The company has a market cap of $25.29 billion, a PE ratio of -31.02, a P/E/G ratio of 7.73 and a beta of 0.49. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. The business has a fifty day moving average of $248.24. Beigene has a one year low of $141.31 and a one year high of $287.88.

Beigene (NASDAQ:ONC) last posted its earnings results on Thursday, February 27th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55). Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The company had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.09 billion.

Insider Activity at Beigene

In other Beigene news, COO Xiaobin Wu sold 30,654 shares of Beigene stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $240.74, for a total value of $7,379,643.96. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Chan Henry Lee sold 1,202 shares of Beigene stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $258.04, for a total value of $310,164.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,146,048 shares of company stock valued at $295,198,300. 6.62% of the stock is owned by company insiders.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.